MX2013004832A - Compuestos y composiciones para el tratamiento del cancer. - Google Patents

Compuestos y composiciones para el tratamiento del cancer.

Info

Publication number
MX2013004832A
MX2013004832A MX2013004832A MX2013004832A MX2013004832A MX 2013004832 A MX2013004832 A MX 2013004832A MX 2013004832 A MX2013004832 A MX 2013004832A MX 2013004832 A MX2013004832 A MX 2013004832A MX 2013004832 A MX2013004832 A MX 2013004832A
Authority
MX
Mexico
Prior art keywords
formula
compounds
cancer
treatment
compositions
Prior art date
Application number
MX2013004832A
Other languages
English (en)
Other versions
MX365807B (es
Inventor
Boulos Zacharie
Lyne Gagnon
Pierre Laurin
Christopher Penney
Brigitte Grouix
Lilianne Geerts
Original Assignee
Prometic Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prometic Biosciences Inc filed Critical Prometic Biosciences Inc
Publication of MX2013004832A publication Critical patent/MX2013004832A/es
Publication of MX365807B publication Critical patent/MX365807B/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/30Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
    • C07C57/32Phenylacetic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/18Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to carbon atoms of six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/40Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/42Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton with carboxyl groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by saturated carbon chains
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/52Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/30Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/46Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings and other rings, e.g. cyclohexylphenylacetic acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/46Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings and other rings, e.g. cyclohexylphenylacetic acid
    • C07C57/48Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings and other rings, e.g. cyclohexylphenylacetic acid having unsaturation outside the aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40Unsaturated compounds
    • C07C59/42Unsaturated compounds containing hydroxy or O-metal groups
    • C07C59/52Unsaturated compounds containing hydroxy or O-metal groups a hydroxy or O-metal group being bound to a carbon atom of a six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40Unsaturated compounds
    • C07C59/42Unsaturated compounds containing hydroxy or O-metal groups
    • C07C59/54Unsaturated compounds containing hydroxy or O-metal groups containing six-membered aromatic rings and other rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40Unsaturated compounds
    • C07C59/76Unsaturated compounds containing keto groups
    • C07C59/84Unsaturated compounds containing keto groups containing six membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C62/00Compounds having carboxyl groups bound to carbon atoms of rings other than six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C62/18Saturated compounds containing keto groups
    • C07C62/20Saturated compounds containing keto groups with a saturated six-membered ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C63/00Compounds having carboxyl groups bound to a carbon atoms of six-membered aromatic rings
    • C07C63/04Monocyclic monocarboxylic acids
    • C07C63/06Benzoic acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C63/00Compounds having carboxyl groups bound to a carbon atoms of six-membered aromatic rings
    • C07C63/04Monocyclic monocarboxylic acids
    • C07C63/06Benzoic acid
    • C07C63/08Salts thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Nuevos usos para compuestos de carboxilato de fenilcetona y compuestos aromáticos sustituidos de Fórmula I, Fórmula I.1, Fórmula I.2, Fórmula lA, Fórmula IB, Fórmula IC y Fórmula II y sus sales farmacéuticamente aceptables para el tratamiento del cáncer. Se describe el uso de una combinación de dos de estos compuestos y el uso de la combinación de uno de estos compuestos con un agente anticanceroso, tal como decarbazina, doxorrubicina, daunorrubicina, ciclofosfamida, busulfex, busulfán, vinblastina, vincristina, bleomicina, etopósido, topotecán, irinotecán, taxotere, taxol, 5-fluorouracilo, metotrexato, gemcitabina, cisplatino, carboplatino y clorambucilo.
MX2013004832A 2010-10-27 2011-10-26 Compuestos y composiciones para el tratamiento del cáncer. MX365807B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40706910P 2010-10-27 2010-10-27
PCT/CA2011/001179 WO2012097427A1 (en) 2010-10-27 2011-10-26 Compounds and compositions for the treatment of cancer

Publications (2)

Publication Number Publication Date
MX2013004832A true MX2013004832A (es) 2013-05-22
MX365807B MX365807B (es) 2019-06-14

Family

ID=46515034

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2013004832A MX365807B (es) 2010-10-27 2011-10-26 Compuestos y composiciones para el tratamiento del cáncer.
MX2019007010A MX2019007010A (es) 2010-10-27 2013-04-26 Compuestos y composiciones para el tratamiento del cancer.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2019007010A MX2019007010A (es) 2010-10-27 2013-04-26 Compuestos y composiciones para el tratamiento del cancer.

Country Status (25)

Country Link
US (2) US9114118B2 (es)
EP (2) EP2632452B1 (es)
JP (2) JP6007186B2 (es)
KR (2) KR101821646B1 (es)
CN (2) CN105997967B (es)
AU (2) AU2011356583C1 (es)
BR (1) BR112013010507A2 (es)
CA (1) CA2816093C (es)
CL (1) CL2013001152A1 (es)
DK (2) DK2632452T3 (es)
EA (2) EA030038B1 (es)
ES (2) ES2703257T3 (es)
HK (1) HK1189836A1 (es)
IL (2) IL225599A (es)
MX (2) MX365807B (es)
MY (2) MY184343A (es)
NZ (1) NZ610851A (es)
PH (1) PH12016502324A1 (es)
PL (2) PL3443957T3 (es)
PT (2) PT3443957T (es)
SG (2) SG10201807622WA (es)
TR (1) TR201819987T4 (es)
TW (2) TWI620563B (es)
WO (1) WO2012097427A1 (es)
ZA (1) ZA201303035B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6007186B2 (ja) * 2010-10-27 2016-10-12 プロメティック・ファーマ・エスエムティ・リミテッドPrometic Pharma Smt Limited がん治療のための化合物および組成物
TWI689489B (zh) * 2013-03-15 2020-04-01 英商邊緣生物科技有限公司 用於治療肺纖維化、肝纖維化、皮膚纖維化及心臟纖維化之經取代之芳族化合物
RU2560702C1 (ru) * 2014-06-05 2015-08-20 Общество с ограниченной ответственностью "Научно-производственный центр "Амфион" (ООО "НПЦ "Амфион") Фармацевтическая композиция для применения в онкологии
WO2016054728A1 (en) * 2014-10-10 2016-04-14 Prometic Biosciences Inc. Substituted aromatic compounds and pharmaceutical compositions for the prevention and treatment of osteoporosis
ES2794782T3 (es) * 2014-10-10 2020-11-19 Liminal Biosciences Ltd Compuestos de carboxilato de fenilcetona y composiciones farmacéuticas para la prevención y el tratamiento de la osteoporosis
AR102634A1 (es) 2014-11-12 2017-03-15 Prometic Biosciences Inc Compuestos aromáticos sustituidos y composiciones farmacéuticas para la autorreparación y regeneración del tejido
CN106267213A (zh) * 2015-05-27 2017-01-04 聊城市奥润生物医药科技有限公司 环二核苷酸cGAMP在治疗肿瘤联合用药中的应用
SG10201913998YA (en) 2017-07-25 2020-03-30 Taris Biomedical Llc Methods of treating tumor metastasis
EP3890717A4 (en) * 2018-12-05 2022-08-24 Liminal Biosciences Limited USE OF SODIUM 2-(3-PENTYLPHENYL)ACETATE IN THE TREATMENT OF ALSTRÖM SYNDROME
US11246945B2 (en) 2019-06-07 2022-02-15 National Defense Medical Center Cisplatin-loaded microbubbles, pharmaceutical composition for treatment of cancer, method for preparing pharmaceutical compositions and method for treating cancer
CN114436822B (zh) * 2022-01-12 2024-04-16 厦门稀土材料研究所 一枝蒿酮酸和生物碱复盐及其制备方法和用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0268907A3 (en) 1986-11-19 1990-03-21 Carl Richard Thornfeldt Treatment of disease conditions relating to hyperactive organelles
US5605930A (en) * 1991-10-21 1997-02-25 The United States Of America As Represented By The Department Of Health And Human Services Compositions and methods for treating and preventing pathologies including cancer
ITMI20012434A1 (it) * 2001-11-20 2003-05-20 Dompe Spa Acidi 2-aril-propionici e composizioni farmaceutiche che li contengono
CN1169768C (zh) * 2002-04-26 2004-10-06 中国科学院上海有机化学研究所 (4-炔基)-芳香酮酸类化合物、合成方法及应用
EP1578757B1 (en) * 2002-12-27 2014-10-22 Janssen Infectious Diseases BVBA Fluorogenic enzyme substrates and methods of preparation
WO2005009104A2 (en) * 2003-07-16 2005-02-03 Ligand Pharmacueticals Incorporated Benzoic and phenyl acetic acid derivatives as hnf-4 modulators
WO2005010202A2 (en) * 2003-07-16 2005-02-03 Ligand Pharmacueticals Incorporated PHENYL ACETIC ACID DERIVATIVES AS HEPATOCYTE NUCLEAR FACTOR 4α (HNF-4α) MODULATOR COMPOUNDS
US8198328B2 (en) * 2004-01-21 2012-06-12 New York University Treatment of cancer using benzoic acid derivatives
EP2061452B1 (en) * 2006-09-01 2011-10-26 Piramal Life Sciences Limited Anti cancer use of caffeic acid and derivatives
US20110046050A1 (en) * 2007-02-08 2011-02-24 Emisphere Technologies, Inc. Phenylalkylcarboxylic acid delivery agents
WO2009055932A1 (en) 2007-11-02 2009-05-07 Prometic Biosciences Inc. Substituted phenylpropionic acids as stimulators of hematopoiesis and erythropoiesis
NZ584981A (en) 2007-11-02 2012-05-25 Prometic Biosciences Inc Medium-chain length fatty acids and glycerides as nephroprotection agents
AU2008338204B2 (en) * 2007-12-19 2015-03-05 Prometic Pharma Smt Limited Medium-chain length fatty acids, salts and triglycerides in combination with gemcitabine for treatment of pancreatic cancer
DK2427417T3 (da) * 2009-05-04 2014-01-20 Prometic Biosciences Inc Salte af 3-pentylphenyleddikesyre og farmaceutiske anvendelser deraf
SG175855A1 (en) * 2009-05-04 2011-12-29 Prometic Biosciences Inc Substituted aromatic compounds and pharmaceutical uses thereof
JP6007186B2 (ja) * 2010-10-27 2016-10-12 プロメティック・ファーマ・エスエムティ・リミテッドPrometic Pharma Smt Limited がん治療のための化合物および組成物

Also Published As

Publication number Publication date
CN105997967A (zh) 2016-10-12
JP2013544799A (ja) 2013-12-19
CA2816093C (en) 2020-12-01
CN105997967B (zh) 2019-08-23
IL225599A (en) 2017-05-29
EA201791585A1 (ru) 2018-05-31
CA2816093A1 (en) 2012-07-26
US20130217645A1 (en) 2013-08-22
US20150313856A1 (en) 2015-11-05
KR101821646B1 (ko) 2018-01-25
HK1189836A1 (zh) 2014-06-20
IL251083B (en) 2018-07-31
EP3443957B1 (en) 2020-11-25
IL251083A0 (en) 2017-04-30
SG189538A1 (en) 2013-06-28
AU2011356583B2 (en) 2015-12-24
EP2632452A4 (en) 2014-05-07
EP3443957A1 (en) 2019-02-20
JP6007186B2 (ja) 2016-10-12
AU2016201556B2 (en) 2017-09-14
EA030038B1 (ru) 2018-06-29
KR101943280B1 (ko) 2019-01-28
TWI620563B (zh) 2018-04-11
PL3443957T3 (pl) 2021-05-04
US9439882B2 (en) 2016-09-13
TWI578983B (zh) 2017-04-21
WO2012097427A1 (en) 2012-07-26
MY184343A (en) 2021-04-01
AU2016201556A1 (en) 2016-04-14
KR20130132448A (ko) 2013-12-04
ES2837599T3 (es) 2021-06-30
AU2011356583A1 (en) 2013-05-09
JP2016188247A (ja) 2016-11-04
ZA201303035B (en) 2014-06-25
CL2013001152A1 (es) 2014-01-10
BR112013010507A2 (pt) 2016-08-02
EA201370103A1 (ru) 2013-12-30
AU2011356583C1 (en) 2016-03-17
ES2703257T3 (es) 2019-03-07
PT3443957T (pt) 2020-12-18
EA035494B1 (ru) 2020-06-25
CN103347509B (zh) 2016-06-08
JP6371344B2 (ja) 2018-08-08
DK2632452T3 (en) 2019-01-21
SG10201807622WA (en) 2018-10-30
DK3443957T3 (da) 2020-12-21
IL225599A0 (en) 2013-06-27
EP2632452A1 (en) 2013-09-04
PH12016502324B1 (en) 2019-07-15
MX365807B (es) 2019-06-14
PL2632452T3 (pl) 2019-03-29
PT2632452T (pt) 2019-01-10
TR201819987T4 (tr) 2019-01-21
US9114118B2 (en) 2015-08-25
EP2632452B1 (en) 2018-09-26
KR20180011332A (ko) 2018-01-31
TW201717928A (zh) 2017-06-01
MY162420A (en) 2017-06-15
PH12016502324A1 (en) 2019-07-15
NZ610851A (en) 2015-05-29
TW201305097A (zh) 2013-02-01
CN103347509A (zh) 2013-10-09
MX2019007010A (es) 2019-09-06

Similar Documents

Publication Publication Date Title
PH12016502324A1 (en) Compounds and compositions for the treatment of cancer
NZ598890A (en) Inhibitors of iap
PH12017502141A1 (en) Compounds and their methods of use
MX2011011661A (es) Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750.
NZ718826A (en) Pyrrolobenzodiazepines and conjugates thereof
GEP201606555B (en) Compounds and compositions for modulating egfr activity
MA34064B1 (fr) Compose heterocyclique
CL2011000504A1 (es) Compuestos derivados de piridin-4-il-tiazol-2il-amida 2-amida-pirrolidin-1,2-dicarboxilico, inhibidores de quinasa de fosfatidil-inositol-3; composicion farmaceutica que comprende a uno de los compuestos; y uso de los compuestos en la preparacion de un medicamento para el tratamiento del cancer.
MY188911A (en) Methods of treating bladder cancer
MY165624A (en) N-acylsulfonamide apoptosis promoters
BR112014013526A2 (pt) conjugados de anticorpo-fármaco e compostos, composições e métodos relacionados
GEP201706691B (en) Substituted phthalazin-1 (2h)-one derivatives as selecti- ve inhibitors of poly (adp-ribose) polymerase-1
MX2010013682A (es) Derivados de 2,4-diamino-l,3,5-triazina triciclicos utiles para el tratamiento del cancer y trastornos mieloproliferativos.
MX2012008328A (es) Derivados de pirazina.
EA201390008A1 (ru) Новые ариламидные производные, обладающие антиандрогенными свойствами
WO2014089177A3 (en) Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines
WO2010027424A3 (en) 9-substituted phenanthrene based tylophorine derivatives
CO6341625A2 (es) Derivados de indol como agentes anticáncer
MX2015007116A (es) Nuevos derivados de 1,4-ditiina sustituida y su uso como fungicidas.
MX2009009657A (es) Fluoroquinolonas para el tratamiento, reduccion, mejora, o prevencion de las infecciones provocadas por las bacterias resistentes a los farmacos antibacterianos.
TW200800993A (en) Organic compounds
MX2015012600A (es) Compuestos de tetrahidroisoquinolina-2-il-(quinazolina-4-il) metanona como inhibidores del crecimiento de células cancerígenas.
MX2012007253A (es) Derivados triciclicos y sus usos y composiciones farmaceuticas.
MX341492B (es) Nuevas formas solidas de 1,1-dioxo-4-tiomorfolinil)-[6-[[3(4-fluor ofenil)-5-metil-4-isoxazolil]metoxi]-3-piridinil]-metanona.
MX2011008069A (es) Uso de inhibidores de topoisomerasa i para tratar el cancer.

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: PROMETIC PHARMA SMT LIMITED

FG Grant or registration